Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03260491 · ClinicalTrials.gov registry record · Phase 1

U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

A Phase 1 study of Non-small Cell Lung Cancer (NSCLC), sponsored by Daiichi Sankyo.

Active
Registry status
Phase 1
Development phase
312
Enrollment target
20
Study locations

NCT03260491 is a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) that is active but no longer recruiting, run by Daiichi Sankyo. The registered enrollment target is 312 participants, above the 283-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (10% higher). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03260491, a Phase 1 study of Non-small Cell Lung Cancer (NSCLC), is active but no longer recruiting, sponsored by Daiichi Sankyo.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
312 participants
Enrollment target
20
Study locations

Study Summary

This study was designed to evaluate safety and antitumor activity of HER3-DXd in two parts: Dose Escalation and Dose Expansion. In Dose Escalation, HER3-DXd was evaluated in participants with metastatic or unresectable NSCLC with epidermal growth factor receptor (EGFR) activating mutation after disease progression during/after EGFR tyrosine kinase inhibitor (TKI) therapy. In Dose Expansion, HER3-DXd will be evaluated in participants with metastatic or unresectable NSCLC with EGFR activating mutation or squamous or non-squamous NSCLC (ie, without EGFR-activating mutations) with disease progression during/after systemic treatment for locally advanced or metastatic disease. In addition, HER3-DXd will be evaluated in participants with locally advanced or metastatic NSCLC whose tumors harbor a KRAS-G12C mutation after progression on the most recent line of therapy (Cohort 5).

Conditions Studied

Non-small Cell Lung Cancer (NSCLC)

Interventions

  • DRUG HER3-DXd (FL-DP)
  • DRUG HER3-DXd (CTM-1 Lyo-DP)
  • DRUG HER3-DXd (CTM-3 Lyo-DP)

Study Locations (20)

Other

  • National Cancer Center Hospital East (NCCHE) - Kashiwa Campus - Kashiwa-Shi
  • Kurume University - Kurume University Hospital - Respiratory Diseases Center - Kurume-Shi
  • Kindai University Hospital - Osaka
  • Shizuoka Cancer Center - Shizuoka

California

  • City of Hope - Duarte
  • University of California San Diego - La Jolla
  • Pacific Shores Medical Group - Long Beach

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana-Farber Cancer Institute - Boston

Michigan

  • Karmanos Cancer Institute - Detroit
  • Henry Ford Hospital - Detroit

New York

  • NYU Langone Health - NYU Medical Oncology Associates - New York
  • Memorial Sloan-Kettering Cancer Center - New York

Washington

  • Fred Hutchinson Cancer Center - Seattle
  • Northwest Medical Specialties - Tacoma

Georgia

  • Winship Cancer Institute of Emory University - Atlanta

Ohio

  • Gabrail Cancer Center (GCC) - Canton Facility - Canton

Trial Details

FieldValue
Enrollment Target 312 participants
Start Date 2017-10-30
Est. Completion 2026-12-31
Phase Phase 1

Sponsor

Daiichi Sankyo

236 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03260491

The ClinicalTrials.gov registry entry for NCT03260491 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 312 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 283-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (10% higher). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 3 interventions - of which HER3-DXd (FL-DP) is the first listed.

NCT03260491 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, California, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03260491 about?

NCT03260491 is a clinical study titled "U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer". This study was designed to evaluate safety and antitumor activity of HER3-DXd in two parts: Dose Escalation and Dose Expansion. In Dose Escalation, HER3-DXd was evaluated in participants with metastatic or unresectable NSCLC with epidermal growth factor receptor (EGFR) activating mutation after dis...

What is the current status of trial NCT03260491?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 312 participants. The study started on 2017-10-30. Estimated completion is 2026-12-31.

What conditions does trial NCT03260491 study?

This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC).

What interventions are being tested in trial NCT03260491?

The interventions under investigation include: HER3-DXd (FL-DP) (DRUG), HER3-DXd (CTM-1 Lyo-DP) (DRUG), HER3-DXd (CTM-3 Lyo-DP) (DRUG).

Who is sponsoring clinical trial NCT03260491?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03260491 being conducted?

This trial has 20 study locations across California, Georgia, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-small Cell Lung Cancer (NSCLC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-small Cell Lung Cancer (NSCLC)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.